High-dose rifamycin vs standard-dose rifamycin in individuals with TB

Treatment with high-dose rifamycin (HDR)-based regimens was not associated with an increased risk for severe adverse events (SAE) compared with standard-dose rifamycin (SDR)-based regimens among patients with tuberculosis (TB) infection, according to results of a study published in Thorax.

Read the full story at Infectious Disease Advisor.

To subscribe to the Weekly Newsletter of new posts, enter your email here:


By Bradley van Paridon

Published: Feb. 11, 2022, 9:05 p.m.

Last updated: Nov. 14, 2024, 7:51 p.m.

Tags: Treatment

Print Share